Page 85 - 2025中醫藥與天然藥物聯合學術研討會-中醫藥與天然藥物的挑戰Ｘ機遇與未來大會手冊

江季霖 教授 Chi-Ling Chiang, PhD

◼ Position/Affiliation/E-mail
Position/Affiliation:

Assistant Professor, Institute of Biopharmaceutical Sciences, National Yang
Ming Chiao Tung University.
Email: clchiang@nycu.edu.tw

◼ Biography
Dr. Chi-Ling Chiang is an Assistant Professor at National Yang Ming Chiao Tung University,
specializing in cancer biology, therapeutic immunology, and drug delivery. Over the past five
years, he has published 17 peer-reviewed articles, including five as first author, with his work

cited more than 1,800 times. His research highlights expertise in both nanoparticle engineering
and exosome-based therapeutics for precision medicine. Dr. Chiang first gained international
recognition for pioneering immunoliposomal microRNA-29 (miR-29)-based nanoparticle
delivery systems for chronic lymphocytic leukemia (CL Chiang, et al. Blood. 2019). He further

advanced understanding of leukemia stem cell resistance and oncogenic mechanisms (CL
Chiang, et al. Cell Reports. 2022). Building on this foundation, his recent work has focused on
engineering extracellular vesicles (EVs) and dual-targeting nanoparticles as next-generation
RNA carriers. He led the design of EV-based systems that deliver therapeutic RNA into

pancreatic tumors with high specificity, achieving significant antitumor efficacy in preclinical
models (CL Chiang, et al. Nature Communications 2023). Beyond therapy, Dr. Chiang
integrates nanotechnology with diagnostics. He co-developed a liquid biopsy platform using
exosomal Glypican-1 to improve early detection of pancreatic cancer, published in (H Li and

CL Chiang, et al. Advanced Science 2024, co–first author). More recently, he advanced small
cell lung cancer diagnostics by developing a DLL3-targeted microchip system capable of
capturing tumor-derived EVs from blood samples, achieving 80–90% diagnostic accuracy (H
Li and CL Chiang, et al. Advanced Science 2025, co–first author). Dr. Chiang’s research bridges

nanomedicine, exosome biology, and translational oncology, aiming to transform therapeutic
delivery and early cancer detection.

63